We sincerely thank Kaewdech and Sripongpun [1] for their insightful editorial and discussion of our study [2] concerning bile acid (BA) dynamics during and after BLV treatment in patients with chronic hepatis D (CHD). We fully agree with their interpretation that BA elevations under bulevirtide therapy primarily reflect on-target NTCP inhibition (i.e., pharmacodynamics) rather than antiviral efficacy.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Marlene
Contact Marlene, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack